Switch theme
Sign up to access all valuation multiples
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain with various other products in the pipeline. Its revenue is mainly generated in the United States.
2012
41
LTM Revenue $8.7M
LTM EBITDA -$17.8M
$156M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hyloris Pharmaceuticals has a last 12-month revenue of $8.7M and a last 12-month EBITDA of -$17.8M.
In the most recent fiscal year, Hyloris Pharmaceuticals achieved revenue of $2.2M and an EBITDA of -$16.1M.
Hyloris Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hyloris Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $3.2M | $2.2M | XXX | XXX | XXX |
| Gross Profit | $3.2M | $3.1M | XXX | XXX | XXX |
| Gross Margin | 101% | 137% | XXX | XXX | XXX |
| EBITDA | -$11.1M | -$16.1M | XXX | XXX | XXX |
| EBITDA Margin | -351% | -718% | XXX | XXX | XXX |
| Net Profit | -$12.4M | -$11.6M | XXX | XXX | XXX |
| Net Margin | -392% | -516% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Hyloris Pharmaceuticals's stock price is EUR 6 (or $6).
Hyloris Pharmaceuticals has current market cap of EUR 168M (or $180M), and EV of EUR 146M (or $156M).
See Hyloris Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $156M | $180M | XXX | XXX | XXX | XXX | $-0.64 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Hyloris Pharmaceuticals has market cap of $180M and EV of $156M.
Hyloris Pharmaceuticals's trades at 18.0x LTM EV/Revenue multiple, and -8.8x LTM EBITDA.
Analysts estimate Hyloris Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Hyloris Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $156M | XXX | XXX | XXX |
| EV/Revenue | 69.8x | XXX | XXX | XXX |
| EV/EBITDA | -9.7x | XXX | XXX | XXX |
| P/E | -10.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -10.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHyloris Pharmaceuticals's NTM/LTM revenue growth is 112%
Hyloris Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Hyloris Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Hyloris Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Hyloris Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -29% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -718% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 45% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -606% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 266% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 691% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 855% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hyloris Pharmaceuticals acquired XXX companies to date.
Last acquisition by Hyloris Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Hyloris Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Hyloris Pharmaceuticals founded? | Hyloris Pharmaceuticals was founded in 2012. |
| Where is Hyloris Pharmaceuticals headquartered? | Hyloris Pharmaceuticals is headquartered in Belgium. |
| How many employees does Hyloris Pharmaceuticals have? | As of today, Hyloris Pharmaceuticals has 41 employees. |
| Is Hyloris Pharmaceuticals publicy listed? | Yes, Hyloris Pharmaceuticals is a public company listed on BRU. |
| What is the stock symbol of Hyloris Pharmaceuticals? | Hyloris Pharmaceuticals trades under HYL ticker. |
| When did Hyloris Pharmaceuticals go public? | Hyloris Pharmaceuticals went public in 2020. |
| Who are competitors of Hyloris Pharmaceuticals? | Similar companies to Hyloris Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Hyloris Pharmaceuticals? | Hyloris Pharmaceuticals's current market cap is $180M |
| What is the current revenue of Hyloris Pharmaceuticals? | Hyloris Pharmaceuticals's last 12-month revenue is $8.7M. |
| What is the current EBITDA of Hyloris Pharmaceuticals? | Hyloris Pharmaceuticals's last 12-month EBITDA is -$17.8M. |
| What is the current EV/Revenue multiple of Hyloris Pharmaceuticals? | Current revenue multiple of Hyloris Pharmaceuticals is 18.0x. |
| What is the current EV/EBITDA multiple of Hyloris Pharmaceuticals? | Current EBITDA multiple of Hyloris Pharmaceuticals is -8.8x. |
| What is the current revenue growth of Hyloris Pharmaceuticals? | Hyloris Pharmaceuticals revenue growth between 2023 and 2024 was -29%. |
| Is Hyloris Pharmaceuticals profitable? | Yes, Hyloris Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
